AcuFAB™ Is Epic's Engine For Growth And The Foundation For Epic's
Fundamental Value Of $1.06 Per Share
AUSTIN, Texas, Dec. 18, 2012 /PRNewswire/ -- EPIC
Corporation (OTC:EPOR) (the "Company"), a preventive healthcare
technology company, announced that AcuFAB™ is the
engine that drives its future growth and AcuFAB™'s
intangible asset value of $17,005,963
is the foundation for EPIC's Fundamental Value of $1.06 per share .
"AcuFAB™ a proprietary acupressure industrial and
medical textile took approximately one year to develop and is
produced in the United States,"
said Ronald Tucker, CEO of EPIC
Corporation. "It is a specialty therapeutic spacer fabric with
a complex architecture and a new and unique but simple
design. It was developed and is produced by Highland
Industries, Inc., a Takata Company and a leader in the industrial
textile markets, in a 700,000 square foot production facility in
South Carolina."
Description
AcuFAB™'s unique design has a single flat surface
with alternating ridges running down the length of the knitted 100%
polyester fabric. The ridges provide a defined and flexible
space and limit the pressure points contacting the body and give a
gentle message effect, while the channels between the alternating
ridges allow for greater circulation and ventilation.
Features
AcuFAB™'s features include:
- Limits pressure points against surface tissues of the
body;
- Is antibacterial – it is resistant to mold and mildew;
- Is hypoallergenic;
- Is hydrophobic and quick drying;
- Retains its shape;
- Is resistant to dyes, solvents, and most chemicals; and
- It has a high melting point.
Benefits
AcuFAB™'s Benefits include:
- Supports body weight across the fabric;
- Allows for more blood and oxygen to reach the surface tissues
of the body;
- Reduces hypertension stress;
- Enhances air circulation which reduces sweating;
- Provides for a more temperate body temperature;
- Can be antibacterial to repeal infectious diseases; and
- Is machine washable and dryer safe.
Markets
AcuFAB™ is unique due to its ability to be used in
fabricating various different types of products in human and animal
market segments. These products can be sold in at least three
large human market segments, medical, home healthcare, and
consumer. In most instances the products made from it do not
require FDA approval.
In July 2012, an independent
company commissioned by EPIC published a market report regarding
the healthcare and medical niche market segments for AcuFAB™ and
its AcuPAD™ products. Click here to download a copy of the
report.
The report only evaluates the mattress overly market relating to
the prevention of pressure sores, and does not discuss the market
for mattress overlays that provide a more comfortable and restful
night's sleep, chair pads, car and truck seat pads, compression
bandages, regular and diabetic shoe inserts, and other products
that can be made with AcuFAB™.
The Market Report provides in-depth (segment) analysis and
market potential for mattress overlays relating to pressure sores.
The AcuPAD™ Mattress overlays provide a more comfortable,
deep un-interrupted sleep. Chair cushions and car and truck
seating pads made from AcuFAB™ provide comfort
and relief from lower back, shoulder and neck pains.
Market Report Summary
The US Supreme Court's decision to uphold the Affordable Care
Act gives more significance to the report. The decision means,
like the report states, healthcare will " gravitate more and more
into preventative medicines and chronic therapeutic regiments . . .
because of large spikes in obesity, diabetes, and an ever
increasing sedentary life style, we are dealing with the increasing
need for handling wounds preemptively . . . . [I]t really will
always be about low blood circulation to surface
tissue." (Market Intelligence Report, June 25, 2012, "Market Summary")
EPIC's AcuPAD™ products, made with
AcuFAB™, "can optimize the way that
both the blood vessels and lymphatic system distributes fluids to
and from the surface tissue. By so doing, it is quite possible
that we can avoid pressure ulcers, diabetic ulcers, and various
other surface tissue lesions caused by a lack of oxygen to these
tissues . . . By facilitating blood flow and by extension oxygen
offload to surface tissues, not only can the inception of these
debilitating sore be prevented but also those that have started to
come about can be addressed early with combination of antibiotics
and circulation management." (ibid.)
Due to the current economic conditions "and incredible pressure
on the healthcare system . . . it would figure that one of the best
ways to handle this is to mitigate . . . bed stays. Not every
one can be helped by prudent [and effective] pressure overlay
methodology, but many patients definitely can be helped and the
amount of money that could be saved is staggering and is in the
billions." (ibid.)
Valuation Summary for AcuFAB™
AcuFAB™ as a physical fabric is a tangible asset valued at cost,
but as an intangible asset its Intrinsic, Fair or Fundamental Value
is determined by a Weighted Average Cost of Capital based on an
estimated gross profit generated from the sale of products made
with AcuFAB™ within a fixed period of time. The Fundamental
Value of projected net revenues and gross profits from
AcuFAB™ products for a 5 year fixed period from the production of
one Highland knitting machine is $17,005,963.
Valuation of EPIC and its Common Stock
The valuation of EPIC's estimated Firm Value and Equity Value
makes use of two Absolute Value Models ("AVM"). One AVM model being
a Present Value Model or Discounted Cash Flow model which derives
value from the present or discounted value of its expected future
sales and income. The two main definitions of cash flow models are
Free Cash Flow to the Firm Model ("FCFF") and Free Cash Flow to
Equity Model ("FCFE"). The Fundamental Firm Value under the
FCFF model is $20,562,126 and the
equity value under the FCFE model is $20,383,171.
The second AVM model is the Relative Valuation. This is an
estimate of an asset's value relative to the value of another
asset. A Relative Valuation is typically implemented using
price multiples or enterprise value multiples in comparison to peer
companies. The relevant price and enterprise value multiples
comparisons are with SPAN, IVC, HRC, the Industry and the
projections of EPIC.
The Relative Values for the Firm is $27,186,777 and the Equity is $27,388,516 with a per stock value of
$1.06
EPIC is a preventative healthcare technology company whose
mission is to provide people with better healthcare through
technology. Visit www.epiccor.com for corporate
information and www.otcmarkets.com for investor information.
CONTACT:
Ronald Tucker CEO
Email: info@eporco.com
Telephone: (866) 737-1413
SOURCE EPIC Corporation
